From Wikipedia, the free encyclopedia
Chemical compound
JNJ-55308942
|
|
Legal status |
|
---|
|
(S)-(3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone
|
CAS Number | |
---|
PubChem
CID | |
---|
|
Formula | C17H12F5N7O |
---|
Molar mass | 425.323 g·mol−1 |
---|
3D model (
JSmol) | |
---|
C[C@H]1CC2=C(CN1C(=O)C3=C(C(=NC=C3)C(F)(F)F)F)N=NN2C4=NC=C(C=N4)F
|
InChI=1S/C17H12F5N7O/c1-8-4-12-11(26-27-29(12)16-24-5-9(18)6-25-16)7-28(8)15(30)10-2-3-23-14(13(10)19)17(20,21)22/h2-3,5-6,8H,4,7H2,1H3/t8-/m0/s1 Key:LMDWZBQISRTEBH-QMMMGPOBSA-N
|
JNJ-55308942 is an investigational drug that works as a
P2X7 antagonist with a downstream effect of reducing
interleukin-1β release.
[1]
[2]
[3] It is developed by
Janssen Pharmaceuticals for
bipolar depression.
[4]
See also
References
-
^ Bhattacharya, Anindya; Lord, Brian; Grigoleit, Jan-Sebastian; He, Yingbo; Fraser, Ian; Campbell, Shannon N.; Taylor, Natalie; Aluisio, Leah; O’Connor, Jason C.; Papp, Mariusz; Chrovian, Christa; Carruthers, Nicholas; Lovenberg, Timothy W.; Letavic, Michael A. (December 2018).
"Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia". Neuropsychopharmacology. 43 (13): 2586–2596.
doi:
10.1038/s41386-018-0141-6.
ISSN
0893-133X.
PMC
6224414.
PMID
30026598.
-
^ Bhattacharya, Anindya; Ceusters, Marc (January 2020).
"Targeting neuroinflammation with brain penetrant P2X7 antagonists as novel therapeutics for neuropsychiatric disorders". Neuropsychopharmacology. 45 (1): 234–235.
doi:
10.1038/s41386-019-0502-9.
ISSN
0893-133X.
PMC
6879571.
PMID
31477815.
-
^ Kolb, Hartmuth C.; Barret, Olivier; Bhattacharya, Anindya; Chen, Gang; Constantinescu, Cristian; Huang, Chaofeng; Letavic, Michael; Tamagnan, Gilles; Xia, Chunfang A.; Zhang, Wei; Szardenings, Anna Katrin (August 2019).
"Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of 18 F-JNJ-64413739, a PET Radioligand for P2X7 Receptors". Journal of Nuclear Medicine. 60 (8): 1154–1159.
doi:
10.2967/jnumed.118.212696.
ISSN
0161-5505.
PMID
30733317.
S2CID
73454130.
-
^
"CTG Labs - NCBI". clinicaltrials.gov. Retrieved 27 November 2023.